Singapore, April 29 -- South Korea-based Samsung Bioepis Co. and China's ATLATL Innovation Center, a global innovation platform for life science research and development, have entered into a Memorandum of Understanding (MoU) on an open innovation programme to accelerate early-stage biotech innovation in Asia-Pacific.

Through this partnership, Samsung Bioepis aims to leverage ATLATL's innovative R&D network and expertise in the Asia-Pacific biotech sector to identify and support promising early-stage biotech companies and breakthrough technologies.

"External innovation is becoming increasingly important in drug development-not only to identify and foster promising early-stage technologies and companies, but also to cultivate a broader in...